Official Medicines Control Laboratory

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VNTR, EQT, INS and OMCL

Retrieved on: 
Monday, August 5, 2019
Civil procedure, Private Securities Litigation Reform Act, Civil law, Lawsuit, Class action, Official Medicines Control Laboratory, Complaint

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.

Key Points: 
  • NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies.
  • If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
  • Get additional information about the OMCL lawsuit: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?w...
    Your ability to share in any recovery doesnt require that you serve as a lead plaintiff.
  • If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq.

OMCL CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Omnicell Inc.

Retrieved on: 
Thursday, August 1, 2019
Laboratories, Official Medicines Control Laboratory

If you purchased Omnicell securities, and/or would like to discuss your legal rights and options please visit Omnicell OMCL Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected] .

Key Points: 
  • If you purchased Omnicell securities, and/or would like to discuss your legal rights and options please visit Omnicell OMCL Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected] .
  • On July 11, 2019, GlassHouse Research LLC published a report entitled Ominous Omnicell, Inc. (OMCL) Delays the Inevitable.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Lifshitz & Miller LLP Announces Investigation of Acer Therapeutics Inc., Aclaris Therapeutics, Inc., Ideanomics, Inc., L Brands, Inc., Marriott International, Inc., NRC Group Holdings Corp., Omnicell, Inc., and OncoCyte Corporation

Retrieved on: 
Friday, July 26, 2019
Laboratories, Official Medicines Control Laboratory, Lifshitz

If you are an ACER investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are an ACER investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are an ACRS investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • Lifshitz & Miller announces investigation into possible securities laws violations in connection with allegations of OMCL engaging in improper accounting revenue practices.
  • The law firm responsible for this advertisement is Lifshitz & Miller LLP, 821 Franklin Avenue, Suite 209, Garden City, New York 11530, Tel: (516)493-9780.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Omnicell, Inc. Investors (OMCL)

Retrieved on: 
Thursday, July 11, 2019
Legal, Professional services, Laboratories, Official Medicines Control Laboratory

Law Offices of Howard G. Smith announces an investigation on behalf of Omnicell, Inc. (Omnicell or the Company) (NASDAQ: OMCL ) investors concerning the Company and its officers possible violations of federal securities laws.

Key Points: 
  • Law Offices of Howard G. Smith announces an investigation on behalf of Omnicell, Inc. (Omnicell or the Company) (NASDAQ: OMCL ) investors concerning the Company and its officers possible violations of federal securities laws.
  • On July 11, 2019, GlassHouse Research LLC published a report alleging that Omnicell prematurely recognized over $38 million in sales.
  • On this news, shares of Omnicell fell as much as 14% during intraday trading, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The University of Tennessee Medical Center Selects Omnicell Solutions to Support Medication Management Strategy

Retrieved on: 
Wednesday, April 24, 2019
Tennessee, University of Tennessee, University of Tennessee Medical Center, Pharmacy, Official Medicines Control Laboratory

MOUNTAIN VIEW, Calif., April 24, 2019 /PRNewswire/ --Omnicell, Inc. (NASDAQ:OMCL) today announced that The University of Tennessee Medical Center in Knoxville will expand its Omnicell automated medication management platform with the addition of new automation for pharmacy and patient care areas.

Key Points: 
  • MOUNTAIN VIEW, Calif., April 24, 2019 /PRNewswire/ --Omnicell, Inc. (NASDAQ:OMCL) today announced that The University of Tennessee Medical Center in Knoxville will expand its Omnicell automated medication management platform with the addition of new automation for pharmacy and patient care areas.
  • These new solutions will streamline workflows and safety initiatives to support improved patient care and enhanced pharmacy performance.
  • UT Medical Center, a 625-bed, not-for-profit academic medical center, serves as a referral center for Eastern Tennessee, Southeast Kentucky and Western North Carolina.
  • For more information about The University of Tennessee Medical Center, visit online at www.utmedicalcenter.org .